Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 5Tumor-Agnostic 1Myeloid 1Genitourinary 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1

Interventions

Cyclophosphamide 229fludarabine phosphate 206fludarabine 163Busulfan 150Mycophenolic Acid 135Tacrolimus 133Whole-Body Irradiation 132Peripheral Blood Stem Cell Transplantation 121Cytarabine 101Azacitidine 100Antilymphocyte Serum 98Melphalan 96Cyclosporine 96Methotrexate 87Imatinib Mesylate 87Filgrastim 85Decitabine 66Granulocyte Colony-Stimulating Factor 60Thiotepa 57venetoclax 53Stem Cell Transplantation 53thymoglobulin 51Radiotherapy 49Cord Blood Stem Cell Transplantation 42nilotinib 40Clofarabine 38Dasatinib 37Methylprednisolone 36ruxolitinib 35Etoposide 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × 2-Propanol × Myeloid × Clear all
NCT03683433 2026-03-05

Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation

M.D. Anderson Cancer Center

Phase 2 Recruiting
50 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡